Dr. Fred R. Hirsch on Unmet Needs in Lung Cancer

The tyrosine kinase inhibitor taletrectinib has been approved for use in patients with ROS1-positive non-small cell lung cancer.

Nicole Gay, APRN-C, shares how nurse navigators can talk to their patients about lung cancer screening.

Tarlatamab prolonged both overall and progression-free survival in the treatment of small cell lung cancer, backing it as a second-line standard of care.

In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.

The oral TKI sevabertinib has been granted priority review for use in patients harboring HER2 mutations in non-small cell lung cancer.

The VENTANA MET (SP44) RxDx Assay is now FDA approved to identify patients with NSCLC eligible for telisotuzumab vedotin.